Journal Article

EZH2 Inhibition to Counteract Oral Cancer Progression through Wnt/β-Catenin Pathway Modulation

Esposito, Emanuela, Lombardo, Sofia Paola, De Gaetano, Federica, Scuderi, Sarah Adriana, Portelli, Marco, Militi, Angela, Colarossi, Lorenzo, Sava, Serena, Campolo, Michela, Paterniti, Irene, Capra, Anna Paola, Bova, Valentina, Filippone, Alessia

2024

Overview

Oral squamous cell carcinoma (OSCC) is one of the most common human malignancies worldwide. The molecular mechanisms of OSCC pathogenesis are still unknown; however, in recent years, several reports have focused on the role of enhancer of zeste homolog 2 (EZH2) in OSCC. Therefore, in this study we aimed to investigate the effects of GSK343, a selective EZH2 inhibitor, and its impact on the signaling pathways in OSCC, using an in vitro and in vivo orthotopic model. In the in vitro model, GSK343 (1, 10, and 25 μM) significantly decreased OSCC cell viability and cell migration through EZH2 inhibition, modulating NF-κB/IκBα pathway activation and eNOS, VEGF, and TGFβ expression, important markers of angiogenesis. In the in vivo model, GSK343 (5 mg/kg and 10 mg/kg) restored tongue tissue architecture and reduced tumor progression through EZH2 inhibition and Wnt/β-catenin signaling pathway modulation. Moreover, GSK343 reduced the expression of inflammatory mediators; eNOS and TGFβ, markers of angiogenesis; and CD31 and CD34, markers of micro vessel density, respectively. In conclusion, our data demonstrate that GSK343 counteracts oral cancer progression through EZH2/Wnt/β-catenin pathway modulation, suggesting that it could be a promising therapeutic approach for OSCC management.

• Publisher: MDPI AG,MDPI
• Subject: angiogenesis / Apoptosis / Cell adhesion & migration / Cell growth / Cytokines / Cytotoxicity / enhancer of zeste homolog 2 / inflammation / Medical prognosis / Metastasis / Oral cancer / oral squamous cell carcinoma / Squamous cell carcinoma / Tumor necrosis factor-TNF / Wnt/β-catenin signaling pathway